New Therapeutic Strategies for Adult Acute Myeloid Leukemia

CPX-351, a liposomal formulation containing daunorubicin and cytarabine, has become one of the standard treatments for secondary AML in the ...

New Therapeutic Strategies for Adult Acute Myeloid Leukemia - PMC

The combination of anthracyclines and cytarabine, called 3 + 7, has been the standard of induction chemotherapy for the treatment of acute myeloid leukemia ( ...

What's New in Acute Myeloid Leukemia (AML) Research?

Improving treatment for acute myeloid leukemia (AML) · Chemotherapy · Stem cell transplants · Targeted therapy drugs · Immunotherapy drugs.

Acute Myeloid Leukemia Treatment - NCI

Treatment options for adult acute myeloid leukemia (AML) include chemotherapy, radiation therapy, stem cell transplant, ...

New directions for emerging therapies in acute myeloid leukemia

Conventional therapy for acute myeloid leukemia is composed of remission induction with cytarabine- and anthracycline-containing regimens, ...

Update on current treatments for adult acute myeloid leukemia

For several decades, the treatment for acute myeloid leukemia (AML) has been a dichotomous choice between intensive chemotherapy strategies ...

Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022

Maintenance therapy with oral azacitidine is now an option for adults with acute myeloid leukemia in first complete remission or complete ...

Study Highlights Promising New Treatment Option for Patients With ...

Study Highlights Promising New Treatment Option for Patients With Treatment-Resistant Acute Myeloid Leukemia · Ziftomenib could be next targeted ...

The landscape of novel strategies for acute myeloid leukemia ...

Furthermore, the innovative therapeutic approaches including hyperthermia, monoclonal antibody-based therapy, and CAR-T cell therapy are also ...

Revumenib Shows Promise for Advanced Acute Myeloid Leukemia

A new type of targeted therapy shows promise for acute myeloid leukemia (AML), one of the most difficult leukemias to treat.

the new approach to acute myeloid leukemia therapy - Nature

Midostaurin was approved by the FDA for therapy in adult patients with newly diagnosed FLT3-mutated AML in April 2017 and was followed by the ...

Typical Treatment of Acute Myeloid Leukemia (Except APL)

If induction chemotherapy (see below) can't be started right away for some reason, sometimes a chemo drug such as hydroxyurea or cytarabine can ...

Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia

Since 2017, the armamentarium for AML has expanded to include new frontline strategies for older or unfit patients, mutation-targeted agents for ...

New Therapeutic Strategies for Adult Acute Myeloid Leukemia

This work reviews new therapeutic strategies for AML that are evolving with the introduction of new drugs in recent years and suggests a suitable strategy ...

Recent advances in targeted therapies in acute myeloid leukemia

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades ...

New therapeutic strategies for high-risk acute myeloid leukemia

There is also a new option for older adults ... Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid.

Acute Myeloid Leukemia: Focus on novel Therapeutic Strategies

The additions of clofarabine for relapsed or refractory disease and the hypomethylating agents represent recent advances. Clinical trials of FLT3 inhibitors ...

Drug therapy for acute myeloid leukemia | Blood - ASH Publications

Although the benefits of this strategy of nonmyeloablative HSCT is currently under investigation,52,53 its ultimate role may be in older adults in first CR who ...

Targeted Therapy Development in Acute Myeloid Leukemia - MDPI

According to recent data from the National Cancer Institute (NCI), the rate of occurrence of new cases of acute myeloid leukemia (AML) per year was 4.1 per ...

New Therapeutic Strategies for Adult Acute Myeloid Leukemia - OUCI

After over 20 years during which no new drugs became available for the treatment of AML, the CD33-targeting antibody–drug conjugate gemtuzumab ozogamicin was ...